Venglustat, another brain-penetrant allosteric inhibitor of GCS, is currently being tested in a global Phase 2 trial to evaluate safety and efficacy in PD patients who are heterozygous for a GBA1 mutation (ClinicalTrials.gov identifier: NCT02906020), supporting this promising strategy of targeting GCS. The gene discussed is GBA1; the disease is Parkinson disease.